In vivo effects of pentaerythrityl-tetranitrate and isosorbide-5-mononitrate on the development of atherosclerosis and endothelial dysfunction in cholesterol-fed rabbits

Journal of Cardiovascular Pharmacology
G KojdaE Noack

Abstract

We wished to determine whether long-term treatment with organic nitrovasodilators has pharmacological effects on the development of atherosclerotic lesions and endothelial dysfunction in cholesterol-fed rabbits. For 15 weeks, six groups of 9 New Zealand White rabbits received a standard diet, which contained no admixture, pentaerythrityl-tetranitrate (PETN 6 mg/kg body weight/day), or isosorbide-5-mononitrate (ISMN 2 mg/kg body weight/day). In the other three groups, the same diets were further enriched with cholesterol (0,75%). Four rings of thoracic aorta were used for tension studies; these rings and the aortas from the aortic arch to bifurcation were then fixed in formol and stained with Sudan IV to determine the area of luminal atherosclerotic lesions by a computerized laser-scanning approach. The cholesterol diet increased plasma levels of cholesterol from 69.8 +/- 10.4 to 907.1 +/- 85.5 mg/dl. A similar result was obtained in the group receiving PETN/cholesterol, but the group fed ISMN/cholesterol showed a significantly higher plasma level of cholesterol (1,165 +/- 81.4 mg/dl). Plasma levels of PETN metabolites were still detectable by gas chromatography/mass spectrometry after a 24-h in vivo washout period. The choleste...Continue Reading

Citations

Dec 4, 2009·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Boris SchnorbusAscan Warnholtz
Jun 12, 2003·Journal of the American College of Cardiology·Senta MüllerGeorg Kojda
Dec 1, 1996·Molecular Medicine Today·H Bult
Sep 19, 2003·Vascular Pharmacology·Eva Kottenberg-AssenmacherGeorg Kojda
May 6, 2009·Clinical and Experimental Pharmacology & Physiology·Darren C HenstridgeBronwyn A Kingwell
Feb 1, 2002·Biochemical and Biophysical Research Communications·Stefanie OberleHenning Schröder
Mar 27, 2009·Journal of Cellular and Molecular Medicine·Marc OppermannGeorg Kojda
Jul 20, 2007·European Journal of Clinical Investigation·J Bauersachs, T Thum
Jul 1, 2008·British Journal of Pharmacology·M OppermannG Kojda
Oct 10, 2014·British Journal of Pharmacology·O PechánováP Ferdinandy
Mar 19, 2013·Journal of the American College of Cardiology·Rio P JuniAn L Moens
Sep 11, 2004·Journal of the American College of Cardiology·Senta MüllerGeorg Kojda
Sep 15, 2004·Journal of the American College of Cardiology·Tatsiana SuvoravaGeorg Kojda
Jul 20, 2007·Arteriosclerosis, Thrombosis, and Vascular Biology·David D Gutterman
Jan 27, 2007·Arteriosclerosis, Thrombosis, and Vascular Biology·Thomas ThumJohann Bauersachs
Feb 7, 2009·Birth Defects Research. Part B, Developmental and Reproductive Toxicology·Michael J QuinnMark S Johnson
Jan 22, 1998·Journal of Cardiovascular Pharmacology·B Fink, E Bassenge
Aug 22, 2020·American Journal of Physiology. Heart and Circulatory Physiology·Hongyan KangXiaoyan Deng
Jan 31, 2009·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Tommaso Gori, Andreas Daiber
Apr 24, 2003·Experimental Biology and Medicine·Stefanie OberleHenning Schröder
Dec 17, 2009·American Journal of Physiology. Heart and Circulatory Physiology·Tamás Csont
Feb 3, 2011·Annals of Medicine·Tommaso Gori, Thomas Münzel
Jul 16, 1999·Biochemical and Biophysical Research Communications·S OberleH Schröder

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.